Evotec (EVO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$831.0M

Revenue (quarter)

$163.8M

Revenue growth (year over year)

−18.72%

Gross profit (trailing twelve months)

$71.2M

Gross margin

8.57%

Net income (trailing twelve months)

−$225.6M

Net income (quarter)

−$53.3M

Net income growth (year over year)

−4.08%

Net margin

−27.15%

Return on equity

−25.71%

EPS (trailing twelve months)

−$0.64

Book value per share

$2.14

P/E (trailing twelve months)

—

Price to book

0.63

Debt to assets

57.71%

Payout ratio

—

Dividend yield

—

Company profile

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

• Is Evotec (EVO) profitable?

  No. Evotec reported a net loss of $225.6M over the trailing twelve months.

• How much revenue does Evotec (EVO) make?

  Evotec generated $831.0M in revenue over the trailing twelve months, down 18.72% year over year.

• How do I buy stock in Evotec (EVO)?

  EVO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.